Brief: Virpax Pharmaceuticals Inc Novvae To Focus Exclusively On Otc Product Candidates
18/09/2023 13:04
Sept 18 (Reuters) - Virpax Pharmaceuticals Inc VRPX.O :
* VIRPAX PHARMACEUTICALS INC: NOVVAE TO FOCUS EXCLUSIVELY ON
OTC
PRODUCT CANDIDATES
* VIRPAX PHARMACEUTICALS INC- CLINICAL TRIALS FOR VIRPAX RX
PIPELINE ARE ANTICIPATED FOR 2024
* VIRPAX PHARMACEUTICALS: IN ADVANCED DISCUSSIONS FOR GLOBAL
RIGHTS OF FIRST REFUSAL ON TWO DIFFERENTIATED NON-PRESCRIPTION
ASSETS
* VIRPAX PHARMACEUTICALS INC: FORMED A NEW WHOLLY-OWNED
SUBSIDIARY
NOVVAE PHARMACEUTICALS
* VIRPAX PHARMACEUTICALS INC: ALSO LOOKING TO ADVANCE
ENVELTA AND
EXPECT TO ENTER PHASE 1 HUMAN CLINICAL TRIALS NEXT YEAR
Source text for Eikon: ID:nBw6nm0pLa
Further company coverage: VRPX.O
Recent news on Virpax Pharmaceuticals
See all newsVirpax Pharma plunges as Nasdaq delisting looms
Brief: Virpax Pharmaceuticals Files For Offering On Best Efforts Basis Up To 2.4 Million Shares Of Common Stock
Brief: Virpax receives positive Probudur™ results for dose range study
Brief: Virpax Looking To Use Met To Develop Intranasal Covid Vaccine
Brief: Virpax Confirms Positive Results With Us Army With Probudur™ For Combat Care Study